U.S. participant recruited for ATHENA trial by Anaconda Biomed
In the field of neuroendovascular thrombectomy, Anaconda Biomed's ANA Funnel Catheter stands out with the largest capture diameter currently available. This innovative device is designed to facilitate clot removal during stent retriever-based thrombectomy, reducing the risk of clot fragmentation and enhancing safety.
The ANA Funnel Catheter is currently under evaluation in the ATHENA IDE study, a pivotal trial aimed at assessing the safety and effectiveness of the device. The IDE approval for this study was granted by the U.S. Food and Drug Administration in September 2024.
The ATHENA clinical trial is a global, randomised study involving 327 patients. It is a continuation of the ATHENA IDE study and is expected to provide valuable insights into the performance of the ANA Funnel Catheter. However, as of August 2025, no recent updates or findings from the ATHENA clinical trial have been publicly disclosed.
The lack of information may suggest that the trial data remains proprietary or unpublished, or that results have not been recently published or disseminated. For the most current and detailed updates, it is recommended to consult Anaconda Biomed’s official communications, clinical trial registries (such as ClinicalTrials.gov), or recent scientific conference presentations related to cardiovascular device trials.
Anaconda Biomed recently announced the enrolment and treatment of the first U.S. patient in its ATHENA clinical trial. The company aims to complete enrollment in the ATHENA IDE study in the first half of 2026.
The importance of the ATHENA clinical trial cannot be overstated. Stroke ranks among the top three leading causes of death and the primary cause of serious long-term disability. With one in four people over the age of 25 expected to have a stroke in their lifetime, and about 87% of cases classified as ischemic events caused by emboli or thrombotic occlusions in the neurovasculature, the need for effective stroke treatment solutions is paramount.
Trent Reutiman, chief executive officer of Anaconda Biomed, emphasised the significance of the ATHENA clinical trial, stating, "This marks the next important step in advancing our funnel catheter technology for ischemic stroke."
In addition to the ATHENA clinical trial, Anaconda Biomed has previously conducted feasibility studies with the ANA Funnel Catheter, which demonstrated high rates of reperfusion and first-pass success, along with a strong safety profile. The results of these studies, as well as the ANAIS study, have been announced but not yet detailed.
As the ATHENA clinical trial progresses, the medical community eagerly awaits the results that could potentially revolutionise the treatment of ischemic stroke.
The ANA Funnel Catheter, designed for neuroendovascular thrombectomy, is currently under evaluation in the ATHENA clinical trial, a pivotal study focusing on health-and-wellness and medical-conditions like stroke and neurological-disorders. Completion of enrollment is anticipated in the first half of 2026, and the trial's outcomes could significantly impact the treatment of these conditions.
